| abstract |
The present invention relates to an antibody that specifically binds to HER2 / neu, in particular a chimeric 4D5 antibody against HER2 / neu, which has reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and treatment of diseases such as cancer, autoimmune diseases, inflammatory disorders and infectious diseases. A polypeptide of the invention is a polypeptide comprising a chimeric 4D5 immunoglobulin light chain comprising, for example, an N65S substitution. |